Bruker (BRKR) Stock
Global scientific instrument maker for research and diagnostics. Here's the price, business snapshot, and what's worth knowing about Bruker in August 2026.
Bruker Corporation (BRKR) is a US-headquartered maker of scientific instruments used in life sciences, materials research and diagnostics. Its product mix includes mass spectrometers, nuclear magnetic resonance (NMR) systems, X-ray diffraction and imaging platforms, and related consumables and service contracts. With a market capitalisation near $5.9 billion, Bruker sits in the small‑to‑mid cap segment where growth can be driven by R&D spending, academic and pharmaceutical investment, and demand for advanced analytical tools. Strengths include a diversified technology base, recurring service and consumable revenues, and a global sales footprint. Key risks are capital‑equipment cyclicality, competition from larger instrument groups, exposure to currency and supply‑chain pressures, and the need for sustained R&D investment. Investors should treat Bruker as a growth‑oriented industrial/scientific instruments play and note that returns are not guaranteed; values can fall as well as rise. This is general educational information, not personalised investment advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bruker Corporation's stock with a target price of $67.86, indicating strong potential growth.
Financial Health
Bruker Corporation is performing well with strong revenue and cash flow generation, indicating healthy operations.
Dividend
Bruker Corporation's low dividend yield of 0.31% suggests limited returns through dividends. If you invested $1000 you would be paid $3.10 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Engine
Service contracts and consumables provide a steady income stream that can temper equipment‑sale cyclicality, though performance can vary with customer investment cycles.
Global R&D Exposure
Bruker benefits from demand across academia, pharma and industry worldwide, but is exposed to FX, regional funding shifts and supply‑chain risks.
Innovation and Competition
Sustained R&D and selective acquisitions drive product differentiation, while competition from larger instrument groups and the need for capital investment remain ongoing challenges.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
